Navigation Links
MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases

- Preclinical Data Support Rationale for Targeting Pro-Inflammatory Protein -

GAITHERSBURG, Md., April 18, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced the publication of preclinical study data demonstrating a role for high mobility group box protein-1 (HMGB1), a nuclear DNA-binding protein, in the pathology of systemic autoimmune diseases such as systemic lupus erythematosus (SLE or lupus) and rheumatoid arthritis. Data to be published in the May 2007 issue of Nature Immunology show that HMGB1 is an essential component of DNA-immune complexes that stimulate immune cells to produce potent inflammatory proteins. The data supplement earlier preclinical evidence that HMGB1 may be an important factor in the sequence of events that result in severe tissue damage following injury or during chronic inflammation. The data also suggest that a blocking antibody to HMGB1 may provide protection in chronic inflammatory diseases.

"MedImmune is committed to developing innovative treatments for inflammatory diseases, and among our key areas of focus are the disease pathology of lupus and the role of B cells in autoimmunity," said Anthony J. Coyle, vice president, research and development, and head, inflammation and autoimmunity research. "These data, applicable to several programs within our pipeline, demonstrate a novel mechanism by which HMGB1 mediates B cell activation and may contribute to the pathogenesis of autoimmune disorders."

HMGB1's potential role in chronic inflammatory diseases is the focus of ongoing preclinical research conducted by MedImmune in collaboration with its partner, Critical Therapeutics, Inc. The Nature Immunology article, titled "Toll-like receptor 9-dependent activation by DNA containing immune complexes is mediated by HMGB1 and RAGE," contains data showing that HMGB1 is a key component of DNA-immune complexes that stimulate activation of B cells and plasmacytoid den dritic cells (pDCs) via the toll-like receptor 9 pathway (TLR9). Both B cells and pDCs are associated with immune system disorders such as lupus. The data also suggest that HMGB1 DNA-immune complexes augment production of inflammatory proteins by interacting with the receptor for advanced glycation end products (RAGE).

About HMGB1

HMGB1, a pro-inflammatory protein secreted by different cell types, is part of the body's response to trauma and infection. HMGB1 is expressed at high levels beginning 12 to 72 hours after an injury, which is about the time inflammation-associated tissue damage begins. Because of the timing and duration of expression of HMGB1, it may be an important factor in the sequence of events that result in severe tissue damage following injury or during chronic inflammation.

About Lupus

According to the Lupus Foundation of America, approximately 1.5 million Americans may suffer from some form of lupus, a chronic inflammatory disease that causes the body to attack its own tissues and organs, including the skin, joints, blood and kidneys. Treatments for lupus include anti-inflammatory drugs, antimalarials, corticosteroids and drugs approved for other purposes, such as immunosuppressive agents given to cancer patients undergoing chemotherapy or medicines developed to treat patients with arthritis. Lupus occurs about 10 times more frequently in adult females than adult males, and is two to three times more common among African Americans, Hispanics, Asians and Native Americans.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to the research and development of antibodies targeting HMGB1. Such statements reflect management's current views and are based on certain assumptions about the success of this program. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune's filings with the SEC. MedImmune is developing HMGB1-related product candidates for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

CONTACT: Media, Kate Barrett, +1-301-398-4320, or Investors, BeatricePierre, +1-301-398-4905, both of MedImmune, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:MEDI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
Post Your Comments:
(Date:11/25/2015)... -- Today AVACEN Medical announced the issue of United States patent No. 9,192,509 ... This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods of ... Photo - ... ... ...
(Date:11/25/2015)... Ohio , Nov. 25, 2015 ... handle hazardous drug preparations (e.g. pharmacists, pharmacy technicians, ... and veterinary technicians). The chapter also covers all ... drugs (e.g., pharmacies, hospitals, other healthcare institutions, patient ... --> --> ...
(Date:11/25/2015)... 25, 2015  Mindray Medical International ... MR ), a leading developer, manufacturer ... today announced that it will hold ... shareholders at the Company,s Hong Kong office (FLAT/RM ... Edward West Road, Mongkok KL, Hong Kong) ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... TyloHelo Inc , North America’s largest ... accessories help improve the bather experience in the sauna, and the accessories selected ... purist looking for simplicity in design to accessories that encourage a greater expression ...
(Date:11/25/2015)... Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... da Vinci surgical robot is being more and more widely heralded as a breakthrough ... assisted da Vinci method has over traditional laparoscopic surgery is that it can greatly ...
(Date:11/25/2015)... ... ... The McHenry County law firm of Botto Gilbert Lancaster, PC ... Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the claimant David Adcock ... , According to court documents, Adcock testified that on May 10, 2010 he sat ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s ... learning in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions ... 65 years, Brillianteen has been a treasured tradition for numerous families in the ...
(Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
Breaking Medicine News(10 mins):